Amgen에 대한 매도 수량은 투자자에게 Amgen의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Amgen (NASDAQ:AMGN) 주식, 공매도 수량 보고

Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Biotech

Long Ideas

Health Care

Technicals

Politics

Trading Ideas

General

AMGN

일라이 릴리(NYSE:LLY)의 최근 주가가 하락세를 보이고 있다. 지난해 주가가 26.04% 상승했지만 최근 한 달 동안에는 17.24% 하락했다.

일라이 릴리의 주식은 케네디가 체중 감량 약물을 대상으로 하자 급락

News

Pre-Market Outlook

Markets

MRNA

MSFT

NVDA

TCOM

TSLA

CNN 머니 공포·탐욕 지수는 전반적인 시장 심리가 더 하락했음을 나타내면서 지난 금요일에 &#39;중립&#39; 영역으로 이동했다.금요일(15일) 미국 증시는 다우존스 지수가 장중 300포인트 이상 하락하는 등 하락세로 마감했다. S&amp;P 500 지수는 주간 2.1%의 손실을 기록했고, 나스닥 종합 지수는 3.2% 정도 하락했다. 30개 종목으로 구성된 다우존스 지수는 한 주 동안 1.2% 하락했다.

美 경제지표 발표, 엔비디아와 MS 주가 하락 후 다우 지수 300p 이상 하락: 공포·탐욕 지수는 &#39;중립&#39;

Equities

암젠(NASDAQ:AMGN)의 주가는 실험적인 비만 약물인 마리타이드(MariTide)의 초기 시험에서 골밀도 손실이 밝혀진 후 화요일에 7% 이상 하락했으며, CNBC의 짐 크레이머는 이 소식이 경쟁사인 일라이 릴리(NYSE:LLY)에 이득이 될 수 있다고 언급했다.

암젠이 뼈 위험 데이터를 숨겼다면 일라이 릴리의 부진한 주가에 호재가 될지도: 짐 크레이머

Amgen Inc

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has seen better days. The stock is up 26.04% for the last year but has struggled recently, falling 17.57% over <a href="https://www.benzinga.com/quote/LLY/news">the last month</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png" alt="" class="wp-image-658564" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21061153/Screenshot-2024-11-21-at-4.40.52-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Lilly stock is well below its summer highs and is trading at $746.94 at the time of writing. The once red-hot obesity drugmaker is in the crosshairs of bearish technicals and political uncertainty.
Could the selloff be an overreaction?
Read Also: <a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a>
<h2 class="wp-block-heading">Bearish Signals Galore For LLY Stock</h2>
Lilly stock is trading beneath its eight-, 20-, and 50-day exponential moving averages, firmly positioning it in a bearish trend. The Relative Strength Index (RSI) of 33.02 indicates the stock is teetering on oversold territory, while the MACD at negative 37.55 confirms strong downward momentum.
Even the 200-day simple moving average of $835.76 is now a distant memory, amplifying concerns.
<h2 class="wp-block-heading">Kennedy Sends Drugmakers Tumbling</h2>
The broader selloff in anti-obesity drugmakers like Eli Lilly, Novo Nordisk AS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) has been linked to fears over the possible appointment by President-elect Donald Trump of Robert F. Kennedy Jr. as head of the Department of Health and Human Services.
Investors worry his critical stance on GLP-1 weight-loss treatments could lead to reduced insurance coverage or pricing pressures. While the agency has limited power to enact sweeping changes without Congress, the uncertainty has spooked the market.
<h2 class="wp-block-heading">Still Room To Run?</h2>
For contrarian investors, the fundamentals paint a different picture. Eli Lilly's Zepbound and Mounjaro sales are projected to hit $18 billion by 2026, doubling from 2024 estimates.
Total revenue is expected to climb to $69 billion by 2026, with earnings soaring to $30 per share — more than double the current $13.26.
And at 33.2 times forward earnings (per <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data), the stock's valuation looks far more attractive than its July peak of 57.2 times.
<h2 class="wp-block-heading">What's Next?</h2>
Jim Cramer's take sums up the contrarian sentiment: "This stock is as hated now as it was loved not that long ago. I think it's a buy&#8230; enough on the selling."
For long-term investors, Eli Lilly's dominance in the burgeoning obesity drug market remains a compelling growth story. 
Whether the selloff is a red flag or a golden opportunity may depend on how much faith investors have in the fundamentals.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42097386/cvs-healthcignaunitedhealths-pharmacy-benefit-managers-accuse-ftc-of-overreach-in-effort-to-reshape-drug-rebate-system">Big Pharma&#8217;s Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System</a></li>
</ul>
Photo courtesy of Eli Lilly.

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

Financial giants have made a conspicuous bullish move on Amgen. Our analysis of options history for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $172,165, and 4 were calls, valued at $144,495.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $280.0 and $350.0 for Amgen, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Amgen stands at 1066.0, with a total volume reaching 267.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Amgen, situated within the strike price corridor from $280.0 to $350.0, throughout the last 30 days.
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732128618_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$22.0</td>
<td>$21.4</td>
<td>$21.55</td>
<td>$292.50</td>
<td>$60.3K</td>
<td>70</td>
<td align="right">51</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$21.8</td>
<td>$21.4</td>
<td>$21.5</td>
<td>$292.50</td>
<td>$45.1K</td>
<td>70</td>
<td align="right">51</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$18.0</td>
<td>$17.4</td>
<td>$17.44</td>
<td>$282.50</td>
<td>$43.7K</td>
<td>703</td>
<td align="right">113</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.5</td>
<td>$19.85</td>
<td>$20.5</td>
<td>$280.00</td>
<td>$40.9K</td>
<td>1.7K</td>
<td align="right">7</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$56.1</td>
<td>$53.95</td>
<td>$55.05</td>
<td>$335.00</td>
<td>$38.5K</td>
<td>310</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Following our analysis of the options activities associated with Amgen, we pivot to a closer look at the company's own performance.
<h3>Where Is Amgen Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,464,150, the price of AMGN is up by 1.67%, reaching $284.63.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 76 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Decoding Amgen's Options Activity: What's the Big Picture?

On Monday, Silence Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42046710/silence-therapeutics-presents-late-breaking-phase-2-zerlasiran-data-at-2024-american-heart-associa" rel="noreferrer noopener">levels (≥125 nmol/L)</a>.
These data were presented at the American Heart Association (AHA) Scientific Sessions.
Results showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks.
This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluate the effects of treatment over time, including intervals between doses.
Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted, and no safety concerns emerged with infrequent dosing.
William Blair notes that while Silence's data shows the drug effectively lowers Lp(a) levels, the Q24W dosing schedule may not be competitive. This is due to a decline in Lp(a) reduction between doses.
This dosing schedule could be an option for maintenance after stable Lp(a) reductions are reached. However, the analyst expects more frequent dosing, possibly every three months, to be needed. This may reduce zerlasiran's competitive edge compared to Amgen Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) olpasiran.
The analyst writes, "Silence continues to execute on both the zerlasiran and divesiran lead clinical programs. While data for zerlasiran presented at AHA show that zerlasiran is an efficacious Lp(a) lowering agent over 48 weeks with Q24W dosing, we are incrementally negative on zerlasiran's competitive profile given the waning of Lp(a) lowering between the infrequent doses, which has not been demonstrated with olpasiran at a once-quarterly dosing frequency."
Price Action: SLN stock is down 33.80% at $7.20 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Aclaris </a><a href="https://www.benzinga.com/24/11/42073438/aclaris-stock-soars-as-analysts-see-fresh-momentum-after-strategic-review-and-encouraging-promising-pipeline-developments">Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments</a></li>
</ul>

Analyst Color

Price Target

Analyst Ratings

Movers

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.
Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) fell sharply in today's pre-market trading after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett <a href="https://www.benzinga.com/quote/NGNE">syndrome patient</a>.
Neurogene shares declined 37.7% to $21.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares tumbled 16.1% to $2.29 in pre-market trading after dipping over 20% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares dipped 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) tumbled 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares fell 7% to $6.28 in pre-market trading.</li>
<li>CompoSecure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) shares declined 5.9% to $13.00 in pre-market trading.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 5.4% to $266.21 in pre-market trading following a 4% decline on Friday.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares fell 5% to $11.80 in pre-market trading after jumping 21% on Friday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 4% to $3.67 in pre-market trading.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell 2.4% to $138.51 in pre-market trading after declining more than 3% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

AMAT

CMPO

LAZR

LUNR

NGNE

OMER

PRQR

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, with the index moving to the &#8220;Neutral&#8221; zone on Friday.
U.S. stocks settled lower on Friday, with the Dow Jones falling more than 300 points during the session. The S&amp;P 500 recorded a weekly loss of 2.1%, while the Nasdaq Composite fell around 3.2%. The 30-stock Dow lost 1.2% during the week.
Major tech stocks recorded losses, with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares falling over 3% on Friday, and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) stock losing around 2.8% during the session. However, shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained around 3% on Friday.
Shares of vaccine companies settled lower on Friday after President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dipped over 7%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares declined more than 4% during the session. The SPDR S&amp;P Biotech ETF dipped over 5%, recording its worst week since 2020.
On the economic data front, U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October. U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, topping market estimates of 0.3%
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, communication services, and healthcare stocks recording the biggest losses on Friday. However, utilities and financials stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 306 points to 43,444.99 on Friday. The S&amp;P 500 fell 1.32% to 5,870.62, while the Nasdaq Composite fell 2.24% at 18,680.12 during Friday's session.
Investors are awaiting earnings results from Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), and AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 50.9, the index moved to the &#8220;Neutral&#8221; zone on Friday, versus a prior reading of 58.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone

WIIM

GILD

IONS

VKTX

Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

Wolfe Research analyst Tim Anderson initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Peer Perform rating.

Initiation

Wolfe Research Initiates Coverage On Amgen with Peer Perform Rating

Events

Amgen To Present MITIGATE Phase 3 Study At ACR 2024 Nov. 14-19

Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 25% bearish. Among these notable options, 4 are puts, totaling $137,540, and 4 are calls, amounting to $285,919.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $290.0 to $340.0 for Amgen over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $290.0 to $340.0 in the last 30 days. 
<h3>Amgen Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731600944_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$43.6</td>
<td>$43.55</td>
<td>$43.6</td>
<td>$300.00</td>
<td>$196.2K</td>
<td>25</td>
<td align="right">0</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$52.8</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$340.00</td>
<td>$51.5K</td>
<td>190</td>
<td align="right">19</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.3</td>
<td>$9.2</td>
<td>$10.0</td>
<td>$310.00</td>
<td>$38.0K</td>
<td>1.8K</td>
<td align="right">62</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$15.65</td>
<td>$15.2</td>
<td>$15.45</td>
<td>$290.00</td>
<td>$33.9K</td>
<td>1.5K</td>
<td align="right">30</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$2.95</td>
<td>$2.08</td>
<td>$2.29</td>
<td>$340.00</td>
<td>$26.5K</td>
<td>112</td>
<td align="right">121</td>
</tr>
</tbody>
</table>

<h3>About Amgen</h3>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 856,173, the AMGN's price is down by -2.03%, now at $295.33. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 82 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $360.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein downgraded its action to Outperform with a price target of $380. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Amgen, targeting a price of $380. 
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Neutral, setting a price target of $335. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Amgen, maintaining a target price of $383. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Amgen, targeting a price of $326. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Amgen, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Amgen's Options Frenzy: What You Need to Know

Analysts' ratings for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a low estimate of $215.00. Observing a 3.48% increase, the current average has risen from the previous average price target of $337.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1731592860_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Amgen among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$335.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$326.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$405.00</td>
</tr>
<tr>
<td>Yaron Weber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$383.00</td>
<td>$381.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$380.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$333.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$405.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$362.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$215.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Amgen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Amgen compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Amgen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Amgen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AMGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Amgen analyst ratings.</a>
<h2>Unveiling the Story Behind Amgen</h2>
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
<h3>Amgen's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Amgen's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 23.18%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amgen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 42.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Amgen's ROA stands out, surpassing industry averages. With an impressive ROA of 3.11%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Amgen's debt-to-equity ratio surpasses industry norms, standing at 8.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Amgen Stock

Citigroup analyst Geoff Meacham initiates coverage on Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral rating and announces Price Target of $335.

Citigroup Initiates Coverage On Amgen with Neutral Rating, Announces Price Target of $335

On Tuesday, a Cantor analyst wrote that additional data from Amgen&#8217;s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
On Wednesday, Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, &#8220;Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41932478/amgen-provides-statement-on-maritide-phase-1-data" rel="noreferrer noopener">later this year</a>.&#8221;
CNBC <a target="_blank" href="https://www.cnbc.com/2024/11/12/amgen-stock-falls-on-weight-loss-drugs-bone-density-loss-data.html" rel="noreferrer noopener">highlighted</a> that MariTide could be a strong new contender in the weight loss drug market. Unlike current weekly injections from Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), MariTide is taken once a month and works through a different mechanism.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41928127/jim-cramer-says-eli-lillys-pathetic-stock-performance-could-get-a-breather-if-amgen-has-hidden-bone-risk-data-after-7-stock-drop" rel="noreferrer noopener">Jim Cramer Says Eli Lilly&#8217;s &#8216;Pathetic&#8217; Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop</a>
Analysts referred to new public data from a phase one study, showing that the highest dose of MariTide (420 milligrams) was associated with around 4% decrease in bone mineral density over 12 weeks.
Goldman Sachs responded that after reviewing the data, they do not believe it shows any safety issues.
Goldman Sachs says BMD measurements from DEXA scans and believes concerns about the data are not justified as there is no significant difference between the treatment and placebo, nor any clear dose-dependent effect in the DEXA data.
The analyst also says a study by Amgen&#8217;s deCODE genetics, which included data from 1.2 million people, found no link between obesity-related variants in the GIPR gene and a higher risk of fractures or lower BMD. It&#8217;s already well-established that rapid weight loss is linked to BMD loss.
William Blair notes that at lower doses of AMG 133 (140 mg and 280 mg), the reduction in bone mineral density is minimal, around 2% at most, which might not differ significantly from the placebo due to limited data in smaller groups.
While the 4% reduction stands out compared to typical reductions of 2% to 2.5%, bariatric surgery has been known to reduce BMD by 3% to 5% after six months.
MariTide, which leads to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">more significant weight loss</a> over six months than semaglutide or liraglutide, may also result in greater BMD reductions due to this weight change.
Price Action: AMGN stock is up 1.39% at $302.98 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a></li>
</ul>

Large Cap

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density

- UBS Healthcare Conference
<a href="https://www.ubs.com/global/en/investment-bank/ib-conferences/americas/global-healthcare-conference/overview.html" title="https://www.ubs.com/global/en/investment-bank/ib-conferences/americas/global-healthcare-conference/overview.html">https://www.ubs.com/global/en/investment-bank/ib-conferences/americas/global-healthcare-conference/overview.html</a>

Amgen Executive Says Co Continues To Be "Laser Focused" On A Phase Three Development Program For Its Obesity Drug Maritide; Says Co Has Not Seen Any Association Between Administration Of Maritide And Bone Mineral Density Changes Or Safety Signals For Bone; Believe That A Research Note Had Suggested "An Inappropriate Inference" Of Maritide Data Given Its Limitations

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$87.00</td>
<td>$27.8K</td>
<td>600</td>
<td>3.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$70.00</td>
<td>$71.9K</td>
<td>2.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$11.00</td>
<td>$41.8K</td>
<td>250</td>
<td>926</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$320.00</td>
<td>$376.7K</td>
<td>1.6K</td>
<td>760</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$65.00</td>
<td>$645.0K</td>
<td>1</td>
<td>750</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$55.00</td>
<td>$112.1K</td>
<td>1.7K</td>
<td>726</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>445</td>
<td>431</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$23.00</td>
<td>$95.7K</td>
<td>4.2K</td>
<td>288</td>
</tr>
<tr>
<td>PTGX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$38.1K</td>
<td>48</td>
<td>268</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$35.5K</td>
<td>1.1K</td>
<td>157</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we notice a put option sweep that happens to be neutral, expiring in 9 day(s) on November 22, 2024. This event was a transfer of 316 contract(s) at a $87.00 strike. This particular put needed to be split into 38 different trades to become filled. The total cost received by the writing party (or parties) was $27.8K, with a price of $88.0 per contract. There were 600 open contracts at this strike prior to today, and today 3045 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 16 day(s) on November 29, 2024. This event was a transfer of 899 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $71.9K, with a price of $80.0 per contract. There were 2173 open contracts at this strike prior to today, and today 1039 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 416 contract(s) at a $11.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.8K, with a price of $100.0 per contract. There were 250 open contracts at this strike prior to today, and today 926 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on December 20, 2024. Parties traded 352 contract(s) at a $320.00 strike. This particular call needed to be split into 46 different trades to become filled. The total cost received by the writing party (or parties) was $376.7K, with a price of $1070.0 per contract. There were 1630 open contracts at this strike prior to today, and today 760 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a put option trade with bullish sentiment. It expires in 275 day(s) on August 15, 2025. Parties traded 750 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $645.0K, with a price of $860.0 per contract. There were 1 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 210 contract(s) at a $55.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $112.1K, with a price of $533.0 per contract. There were 1798 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option sweep with bullish sentiment. It expires in 219 day(s) on June 20, 2025. Parties traded 85 contract(s) at a $100.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $59.3K, with a price of $695.0 per contract. There were 445 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 2 day(s) on November 15, 2024. Parties traded 174 contract(s) at a $23.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $95.7K, with a price of $549.0 per contract. There were 4250 open contracts at this strike prior to today, and today 288 contract(s) were bought and sold. 
• For PTGX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTGX#NASDAQ">PTGX</a>), we notice a call option sweep that happens to be bearish, expiring in 65 day(s) on January 17, 2025. This event was a transfer of 37 contract(s) at a $35.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $1030.0 per contract. There were 48 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option sweep that happens to be bullish, expiring in 2 day(s) on November 15, 2024. This event was a transfer of 25 contract(s) at a $67.50 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $35.5K, with a price of $1416.0 per contract. There were 1186 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INCY

PTGX

10 Health Care Stocks With Whale Alerts In Today's Session

Live On CNBC, Joe Terranova Announces Sold Amgen

"The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year," Amgen said.

Amgen Issued The Statement On MariTide (Maridebart Cafraglutide, Formerly AMG 133) Phase 1 Data, Saying Amgen Does Not See An Association Between The Administration Of MariTide And Bone Mineral Density Changes

Amgen Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC&#8217;s Jim Cramer suggested the news could benefit rival Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
What Happened: Previously undisclosed data from MariTide&#8217;s Phase 1 trial showed a 4% decrease in bone mineral density among participants receiving a 420mg dose during the 12-week multiple ascending dose study. According to Olivia Brayer of Cantor Fitzgerald, the information emerged from hidden tabs in extended data files related to the trial.
MariTide, positioned as a monthly alternative to weekly injections offered by competitors Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly, operates through a different weight loss mechanism. The drug&#8217;s development has attracted significant attention due to its potential to disrupt the growing obesity treatment market.
&#8220;If Amgen has hidden bone risk data for its obesity drug, that&#8217;s huge news for Lilly which has become a pathetic stock of late,&#8221; Cramer wrote on X, formerly Twitter, announcing plans to discuss the implications at an upcoming meeting.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If Amgen has hidden bone risk data for its obesity drug , that&#39;s huge news for Lilly which has become a pathetic stock of late. Club name.. will talk about it at Thursday&#39;s meeting
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1856424358564245623?ref_src=twsrc%5Etfw">November 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/24/11/41927291/mara-holdings-soundhound-ai-spotify-rivian-tesla-why-these-5-stocks-are-on-investors-radars-today">MARA Holdings, SoundHound AI, Spotify, Rivian, Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
Why It Matters: Despite concerns, Cantor Fitzgerald maintained its Overweight rating on Amgen with a $405 price target. The firm acknowledged that while some bone density loss is expected during weight loss treatments, particularly with a suboptimal diet, the dose-dependent increase in bone density loss could raise red flags.
The analysis also revealed data about AMG 598, a predecessor molecule that Amgen may have been investigating to challenge assumptions about GIPR antagonism&#8217;s role in bone density loss.
Price Action: Eli Lilly stock closed at $818.86 on Tuesday, down 1.63% for the day, with a slight drop of 0.10% in after-hours trading. Despite this, the stock has seen a strong 38.27% increase year-to-date. 
Meanwhile, Amgen ended the day at $298.84, down 7.14%. However, it saw a slight recovery after hours, rising 0.61%. Amgen's stock has gained 0.49% year-to-date, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41927913/amazon-confirms-vendor-data-breach-affecting-2-8m-employee-contacts-adds-to-growing-list-of-moveit-hack-victims">Amazon Confirms Vendor Data Breach Affecting 2.8M+ Employee Contacts, Adds To Growing List Of MOVEit Hack Victims</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop

Jefferies analyst Michael Yee maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Buy and maintains $380 price target.

Jefferies Maintains Buy on Amgen, Maintains $380 Price Target

Amgen shares are trading lower after Cantor Fitzgerald highlighted pipeline risks and a 4% BMD loss in its AMG-133 Phase 1 trial.

Guidance

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Eledon Pharmaceuticals (ELDN –...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Eledon Pharmaceuticals (ELDN)

Geoff Meacham, an analyst from Citi, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target remains the same wit...

Cautious Hold Rating on Amgen's MariTide Amid Safety and Efficacy Concerns

XLV: Healthcare Stocks In Critical Condition (Rating Downgrade)

Amgen (AMGN) announced that Howard Chang will join the company as Senior VP of Research, effective Dec. 16. Chang will also assume the title and re...

Amgen appoints Howard Chang as SVP of Research and Chief Scientific Officer

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $380.00. T...

Jefferies Sticks to Their Buy Rating for Amgen (AMGN)

Optimism over global healthcare sector rises: Jefferies

BMO Capital analyst Evan Seigerman has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday. Evan Seigerman has given his B...

Comments

Amgen

매도 수량

Amgen (NASDAQ:AMGN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌